Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells.

about

Pembrolizumab and salvage chemotherapy in EGFR T790M-positive non-small-cell lung cancer with high PD-L1 expression

P2860

Q58759053-4D7D4E58-F7AB-40DE-98DD-0E82FEF21D5E

P2860

Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells.

Item

http://www.wikidata.org/entity/Q41912025

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Osimertinib (AZD9291) decrease ...... -small cell lung cancer cells.

@en

type

Item

label

Osimertinib (AZD9291) decrease ...... -small cell lung cancer cells.

@en

prefLabel

Osimertinib (AZD9291) decrease ...... -small cell lung cancer cells.

@en

P1476

Osimertinib (AZD9291) decrease ...... n-small cell lung cancer cells

@en

P2093

Le-Le Zhang

http://www.w3.org/2001/XMLSchema#string

Min-Xia Su

http://www.w3.org/2001/XMLSchema#string

Mu-Yang Huang

http://www.w3.org/2001/XMLSchema#string

Xiao-Ming Jiang

http://www.w3.org/2001/XMLSchema#string

Xiuping Chen

http://www.w3.org/2001/XMLSchema#string

Yu-Lian Xu

http://www.w3.org/2001/XMLSchema#string

P2860

GSK-3: tricks of the trade for a multi-tasking kinase

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.

The blockade of immune checkpoints in cancer immunotherapy

The renaissance of GSK3

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

Immunosuppressive networks in the tumour environment and their therapeutic relevance

Pembrolizumab for the treatment of non-small-cell lung cancer

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

P2888

aps.2017.123

P304

1512-1520

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/APS.2017.123

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jinjian Lu

P577

2017-09-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28880013

http://www.w3.org/2001/XMLSchema#string

P932

5672073

http://www.w3.org/2001/XMLSchema#string

Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells.

about

P2860

P2860

Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P932